The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated indolent non-Hodgkin lymphomas (iNHL).
Myron Stefan Czuczman
Research Funding - Gilead Sciences
Hans Knecht
Research Funding - Gilead Sciences
Rebecca Auer
Research Funding - Gilead Sciences
Joseph James McKendrick
Research Funding - Gilead Sciences
Neil Sun Chua
Research Funding - Gilead Sciences
Kim Linton
Research Funding - Gilead Sciences
Graham Collins
Honoraria - Gilead Sciences
Sven De Vos
Research Funding - Gilead Sciences
Leanne Holes
Research Funding - Gilead Sciences
Esteban Abella
Employment or Leadership Position - Gilead Sciences
Stock Ownership - Gilead Sciences
Gilles A. Salles
Research Funding - Gilead Sciences